Pharmaceuticals, Biotechnology and Life Sciences
Arecor Therapeutics has decided to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278, in line with the update provided within its Interim Results on 14 September.
Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a favorable safety and tolerability profile
Eli Lilly’s Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly’s rapid-acting insulin and need a lower-cost option, the company said Wednesday.
Latino population in the United States of America have higher rates of cardio-metabolic diseases than in rest of the population, said David Kerr, director of Innovation and Research for the William Sansum Diabetes center.
UPDATE contains comment from Lilly
Eli Lilly has quit from a research and licence agreement with a Paris-listed clinical stage pharmaceutical company Adocia, the French company said on Friday.
European Commission has granted marketing authorisation for Novo Nordisk’s Fiasp for the treatment of diabetes in adults.
Eli Lilly has announced that people who use Lilly insulin will be able to access discounted prices for their purchases…
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) were granted approval by the U.S. Food and Drug Administration (FDA) for Basaglar (insulin glargine injection) 100 units/mL.
The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…